Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemo-immunotherapy and Stem Cell Transplant in Advanced NK/T-Cell Lymphoma/Leukemia
NCT03719105Phase 1Recruiting
- Sponsor
- New York Medical College
- Start
- Mar 2019
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of methotrexate, pralatrexate, ifosfamide, dexamethasone, etoposide and 6 more in natural killer cell lymphoma (NKCL), natural killer cell leukemia (NKCL) and peripheral T-cell lymphoma (PTCL) (2 cohorts), sponsored by New York Medical College. Primary endpoint: Overall Response Rate at 1 year. Started Mar 2019; status: recruiting.
02
Drugs
methotrexatepralatrexateifosfamidedexamethasoneetoposide
03
Conditions
natural killer cell lymphoma (NKCL)natural killer cell leukemia (NKCL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT03719105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03719105.